Key facts
- Notable investors include Suzhou Oriza Holdings Corporation, Hefei Industry Investment Group, YuanBio Venture Capital, Hillhouse Investment Group, Suzhou Innovation Investment Group — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for XIAOLU Biomedicine
- ·The full record, as it builds
Funding rounds
No funding rounds for XIAOLU Biomedicine are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About XIAOLU Biomedicine
Developer of biologic drugs designed for autoimmune and inflammation therapy purposes. The company's platform integrates a proprietary antibody discovery strategy, a built-in technology platform for generating next-generation large-molecule biologics, target mechanism analysis, combination target screening, and a dedicated R&D team infrastructure, enabling pharmaceutical developers and clinical researchers to pursue more effective and longer-lasting treatments for autoimmune and inflammatory diseases by accelerating progression from early mechanism exploration to candidate selection and scalable preclinical development.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2025
- Ownership
- Privately Held (backing)
XIAOLU Biomedicine doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in XIAOLU Biomedicine shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on XIAOLU Biomedicine in its N-PORT filings yet. We sweep new filings monthly.